Promising Pan-KRAS Inhibitor Data
BlossomHill presents promising preclinical data for its oral pan-KRAS inhibitor across various cancers.
Anonymous
BlossomHill Therapeutics presented preclinical findings on BH-501284, an investigational oral pan-KRAS inhibitor, at an American Association for Cancer Research pancreatic cancer conference. The company reported prolonged target engagement and tumor regression across laboratory models of KRAS-mutant pancreatic, lung and colorectal cancers, with activity spanning several KRAS mutations. BlossomHill said the results support advancing the drug toward an investigational new drug submission planned for the first quarter of 2027; the findings are preclinical and do not establish safety or efficacy in people.
Key Points
1
BlossomHill described BH-501284 as a non-covalent, pseudo-irreversible inhibitor built around a novel Switch-II chemical scaffold, designed for prolonged and selective inhibition of mutant KRAS; the company said it showed cellular activity across KRAS mutations while sparing HRAS and NRAS.
2
In a KRAS G12D pancreatic cancer model, BH-501284 reportedly produced deeper and more durable tumor regression than certain tricomplex RAS inhibitors.
3
In a KRAS G12D colorectal cancer model, combining BH-501284 with anti-PD-1 treatment extended survival, according to the company.
4
CEO Jean Cui said the company designed the drug’s scaffold and binding characteristics to pursue potent, durable KRAS inhibition, which it believes could potentially improve efficacy and tolerability.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
6
Articles
19
Reach
25
A
AnonymousAuthor
